Drug Information

Drug General Information
Drug ID
D06OIV
Former ID
DAP000136
Drug Name
Tolbutamide
Synonyms
Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea
Drug Type
Small molecular drug
Indication Non-insulin dependent diabetes [ICD10:E11.9] Approved [551871]
Therapeutic Class
Hypoglycemic Agents
Company
Pharmacia And Upjohn Co
Structure
Download
2D MOL

3D MOL
Formula
C12H18N2O3S
InChI
InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
InChIKey
JLRGJRBPOGGCBT-UHFFFAOYSA-N
CAS Number
CAS 64-77-7
PubChem Compound ID
5505
PubChem Substance ID
9357, 85591, 640044, 855782, 5658513, 7847446, 7980810, 8144417, 8149557, 8153385, 10321470, 10531694, 11111857, 11111858, 11120087, 11120575, 11121063, 11121572, 11122052, 11147170, 11335516, 11360755, 11362641, 11363341, 11364689, 11365203, 11365903, 11367251, 11367765, 11368465, 11369813, 11370553, 11370554, 11371678, 11372854, 11373366, 11373934, 11375413, 11375927, 11376627, 11377976, 11457019, 11461727, 11466218, 11467338, 11484736, 11485776, 11489026, 11490415, 11492173
ChEBI ID
ChEBI:27999
SuperDrug ATC ID
A10BB03
SuperDrug CAS ID
cas=000064777
Target and Pathway
Target(s) SUR2-type K(ATP) channel Target Info Blocker [536969]
Sulfonylurea receptor 1 Target Info Blocker [536969]
KEGG Pathway ABC transporters
Insulin secretion
Type II diabetes mellitus
Pathway Interaction Database FOXA2 and FOXA3 transcription factor networks
PathWhiz Pathway Muscle/Heart Contraction
Pancreas Function
Reactome ABC-family proteins mediated transport
Regulation of insulin secretion
WikiPathways Potassium Channels
Integration of energy metabolism
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536969Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. doi: 10.1172/JCI35772. Epub 2008 Dec 8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.